Clinical Trial

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-01.
Trial Details
NCT Number NCT06120166
Lead Sponsor He Huang
Collaborators: Leman Biotech Co., Ltd.
Conditions Diffuse Large B-cell Lymphoma
Enrollment 18 participants
Start Date 2023-11-16
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-04-05 (estimated)
Updated on ClinicalTrials.gov 2025-09-19